stockportfolio.pro
ICON Public Limited Company (ICLR)
Healthcare · Diagnostics & Research · NasdaqGS
ICON Public Limited Company revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $7.74B | $8.05B | $8.19B | $8.25B |
| Gross profit | $2.21B | $2.35B | $2.37B | $2.18B |
| Net income | $505.30M | $554.21M | $739.13M | $229.34M |
| Net margin | 6.5% | 6.9% | 9.0% | 2.8% |
Source: ICON Public Limited Company SEC filings (10-K).
What growth is priced into ICLR stock?
At today's market cap of $11.10B, ICON Public Limited Company is priced for free-cash-flow growth of about 1.7% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $861.99M from the FY ending 2025-12-31). This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 4 years of ICON Public Limited Company financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ICLR in your portfolio →
ICON Public Limited Company financial history by metric
About ICON Public Limited Company
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
ICON Public Limited Company — frequently asked questions
What is ICON Public Limited Company's revenue?
ICON Public Limited Company (ICLR) reported revenue of $8.25B for fiscal year 2025, up 0.8% from the prior year, according to its SEC filings.
Is ICON Public Limited Company profitable?
Yes. ICLR earned net income of $229.34M in fiscal 2025, a net margin of 2.8%.
What is ICLR's P/E ratio?
ICON Public Limited Company trades at a price-to-earnings ratio of about 50.0 based on the latest data in our nightly-refreshed cache.
How fast is ICON Public Limited Company growing?
ICLR's revenue grew at roughly 2.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does ICON Public Limited Company have?
As of fiscal year 2025, ICLR carried roughly $3.40B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is ICON Public Limited Company's gross margin?
ICLR's gross margin was 26.4% in fiscal 2025 — gross profit of $2.18B on revenue of $8.25B.
What is ICON Public Limited Company's market cap?
ICON Public Limited Company (ICLR) has a market capitalization of about $11.10B, based on the latest data in our nightly-refreshed cache.
When does ICON Public Limited Company's fiscal year end?
ICLR's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into ICLR stock?
At today's market cap of $11.10B, ICON Public Limited Company is priced for free-cash-flow growth of about 1.7% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $861.99M from the FY ending 2025-12-31).
Where does this data come from?
All figures are computed from ICON Public Limited Company's official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.